CYP2D6 and ABCB1 Genetic variability: Influence on paroxetine plasma level and therapeutic response

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 474-482

  Gex Fabry, Marianne ^a,c   Eap, Chin B ^b   Oneda, Beatrice ^b   Gervasoni, Nicola ^a   Aubry, Jean Michel ^a   Bondolfi, Guido ^a   Bertschy, Gilles ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Hopital de Cery   (Switzerland)

^c Department of Psychiatry ^*  (Sweden)

Author keywords

ABCB1 polymorphisms; CYP2D6 polymorphism; Interindividual variability; Paroxetine plasma concentration; Therapeutic response to paroxetine

Indexed keywords

CLORAZEPATE; CYTOCHROME P450 2D6; GLYCOPROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PAROXETINE; ZOLPIDEM; ABCB1 PROTEIN, HUMAN; ANTIDEPRESSANT AGENT; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PERMEABILITY; PRIORITY JOURNAL; TREATMENT RESPONSE; ADOLESCENT; ALGORITHM; ANALYSIS OF VARIANCE; BLOOD; GENETICS; MAJOR DEPRESSION; MASS FRAGMENTOGRAPHY; MIDDLE AGED; PHENOTYPE; PSYCHOLOGICAL RATING SCALE; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENETIC VARIATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PAROXETINE; PHENOTYPE; PSYCHIATRIC STATUS RATING SCALES; YOUNG ADULT;

EID: 58149124253     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31817d6f5d     Document Type: Article

References (60)

1. Dechant KL, Clissold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41:225-253.
2. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992;51: 288-295.
3. Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992;51:278-287.
4. Feng Y, Pollock BG, Ferrell RE, et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol. 2006;61:558-569.
5. Kato M, Fukuda T, Wakeno M, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology. 2006;53:186-195.
6. Serretti A, Benedetti F, Zanardi R, et al. The influence of serotonin transporter promoter polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1074-1084.
7. Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci. 2002; 27:250-257.
8. Findling RL, Nucci G, Piergies AA, et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology. 2006;31: 1274-1285.
9. Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit. 2003;25:738-742.
10. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol. 2004;60:553-557.
11. Ueda M, Hirokane G, Morita S, et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:486-491.
12. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990;18:289-299.
13. Tasker TC, Kaye CM, Zussman BD, et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand. 1989;350(Suppl):152-155.
14. Murphy GM, Jr., Kremer C, Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry. 2003;160: 1830-1835.
15. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004;75:13-33.
16. Leschziner GD, Andrew T, Pirmohamed M, et al. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007;7: 154-179.
17. Wang D, Johnson AD, Papp AC, et al. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005;15:693-704.
18. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525-528.
19. Jeannesson E, Albertini L, Siest G, et al. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundam Clin Pharmacol. 2007;21:411-418.
20. Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006;80:668-681.
21. Ishikawa T, Tsuji A, Inui K, et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics. 2004;5: 67-99.
22. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry. 2003;54:840-846.
23. Weiss J, Dormann SM, Martin-Facklam M, et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003; 305:197-204.
24. Yasui-Furukori N, Saito M, Niioka T, et al. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther Drug Monit. 2007;29:45-48.
25. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33:165-174.
26. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:398-404.
27. Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57:203-209.
28. Bondolfi G, Aubry JM, Golaz J, et al. A stepwise drug treatment algorithm to obtain complete remission in depression: a Geneva study. Swiss Med Wkly. 2006;136:78-85.
29. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. Geneva: WHO; 1993.
30. Montgomery SA, Å sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
31. Eap CB, Bouchoux G, Amey M, et al. Simultaneous determination of human plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. J Chromatogr Sci. 1998;36:365-371.
32. Eap CB, Fellay J, Buclin T, et al. CYP3A activity measured by the midazolam test is not related to 3435C>T polymorphism in the multiple drug resistance transporter gene. Pharmacogenetics. 2004;14:255-260.
33. Schaeffeler E, Schwab M, Eichelbaum M, et al. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat. 2003;22:476-485.
34. Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996;392:30-34.
35. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22-33.
36. Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry. 1984;41: 782-786.
37. Gex-Fabry M, Balant-Gorgia AE, Balant LP, et al. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur J Clin Pharmacol. 2004;59:883-891.
38. Gex-Fabry M, Gervasoni N, Eap CB, et al. Time course of response to paroxetine: influence of plasma level. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:892-900.
39. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
40. Raimundo S, Toscano C, Klein K, et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther. 2004;76:128-138.
41. Maurer TS, Debartolo DB, Tess DA, et al. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos. 2005;33:175-181.
42. Guzey C, Spigset O. Low serum concentrations of paroxetine in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol. 2006;26:211-212.
43. Kuhn UD, Kirsch M, Merkel U, et al. Reboxetine and cytochrome P450-comparison with paroxetine treatment in humans. Int J Clin Pharmacol Ther. 2007;45:36-46.
44. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol. 2004;369:23-37.
45. Toscano C, Klein K, Blievernicht J, et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics. 2006;16:755-766.
46. Kirchheiner J. CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther. 2008;83:225-227.
47. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234-242.
48. DeLeon J. The crucial role of therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol. 2007;27:241-245.
49. Kawanishi C, Lundgren S, Agren H, et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. 2004;59:803-807.
50. Fukui N, Suzuki Y, Sawamura K, et al. Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit. 2007;29:185-189.
51. Yasui-Furukori N, Mihara K, Takahata T, et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol. 2004;57:569-575.
52. Parkinson A, Mudra DR, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 2004;199:193-209.
53. Bebia Z, Buch SC,Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther. 2004;76:618-627.
54. Gex-Fabry M, Rudaz S, Balant-Gorgia AE, et al. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. Eur J Clin Pharmacol. 2002;58:323-331.
55. Paine MF, Ludington SS, Chen ML, et al. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos. 2005;33:426-433.
56. Schuetz EG, Furuya KN, Schuetz JD. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther. 1995;275:1011-1018.
57. Wolbold R, Klein K, Burk O, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology. 2003;38:978-988.
58. Meier Y, Pauli-Magnus C, Zanger UM, et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology. 2006;44:62-74.
59. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64:413-420.
60. Lotrich FE, Bies RR, Smith GS, et al. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol. 2006;20:33-40.